ECCN European Conference on Clinical Neuroimaging - PARIS France 2019

INVITED SPEAKERS IN 2019



SIMON CERVENKA

May 21, 9.10 - 9.40am - "Is synaptic density altered in psychiatric diseases?"

In recent years multiple lines of research has suggested an involvement of the immune system in psychiatric disorders. In schizophrenia, recent observations highlight a role for microglia in overactive pruning. Dr Cervenka will summarize the evidence for immune-related synaptopathy in schizophrenia, and how we can target these processes using molecular imaging.
 

ANDREAS JACOBS

May 20, 2.00 - 2.45pm - "Novel PET tracers: from target identification to clinical applications." 
 
Novel PET tracers: from target identification to clinical application
The lecture will cover the (reverse-)translational research activities of the INMIND consortium (2012-2018) in the attempts to image disease-driving microglia activation based on “novel” radiotracers targeting TSPO as well as alternative microglial targets.

HENRY WOODRUFF

May 21, 11.40am - 12.10pm - "Radiomics: Medical images are not pictures, they are data. Potential application in neuroconcology"
 
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research and has multiple applications in neuro-imaging.
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research and has multiple applications in neuro-imaging.

 

ADRIAAN LAMMERTSMA

May 20, 2.45 - 3.30pm - "Opportunities and pitfalls in quantifying neuroinflammation using PET" 
 
Neuroinflammation is associated with microglia activation. This, in turn, results in increased TSPO expression, which can be imaged by TSPO PET tracers. Quantification of TSPO expression, however, has proven to be difficult due to the low signal to noise ratios obtained with first generation TSPO tracers. Although some second generation TSPO tracers provide higher signal to noise ratios, quantification remains difficult partly because polymorphism. This presentation will provide an overview of efforts to quantify uptake of TSPO ligands, which is possible provided sufficient detail is given to experimental design. In addition, other future prospect of novel non-TSPO ligands associated with neuroinflammation will be discussed.

 

ANDREAS VARRONE

May 21, 8.40 - 9.10am - "Synaptic density in neurodegenerative diseases."

Andrea Varrone, MD, PhD, Associate Professor of Nuclear Medicine at the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. He is research group leader for Molecular brain imaging of neurodegenerative disorders. The focus of his research is the development of PET imaging markers for the study of Parkinson´s disease and dementia. In his talk he will provide an overview on imaging of SV2A in neurodegenerative disorders. 

GIOVANNI FRISONI

May 20, 9.30 - 10.15am - "Present and future of molecular imaging in the clinic" 
 
Imaging is a cornerstone of early and accurate diagnosis of Alzheimer’s disease and other dementias. The use of MRI and the different flavors of PET in the clinic is loaded with scientific uncertainties and societal controversy. Arguments will be offered from the perspective of advancing the field and patient’s best interest.

VALENTINA GARIBOTTO

May 21, 8.40 - 9.10am - "Comparison of FDG and tau PET in the AD spectrum"
 
FDG and tau PET are both important biomarkers of AD, measuring respectively the presence of neurodegeneration and of tau deposits. 
Both phenomena are correlated with the clinical phenotype and severity and thus have a relevant diagnostic and prognostic relevance. 
The presentation will cover the current evidence on the clinical utility of the two biomarkers and on their respective strengths and weaknesses, outlining perspectives of use and priorities for future studies.  

 

MARCO PAGANI

May 21, 12.10 - 12.40pm - "Amyotrophic Lateral Sclerosis and Huntington Disease: towards clinical use of neuroimaging"
 
 
Neuroimaging has been recently implemented to diagnose amyotrophic lateral sclerosis (ALS), to recognize early signs of neurodegeneration in patients with a genetic risk of Huntington’s disease (HD) and to detect the metabolic changes related to cognitive impairment in patients with ALS and HD. The presentation will review the recent advancements in PET and MRI investigations in ALS and HD and will focus on the efforts made to evaluate and validate the incremental value of neuroimaging as useful biomarkers over clinical routine.
 
 
 

MICHEL KOOLE

May 21, 9.40 - 10.10am - "AI in CNS PET/multimodal imaging."

AI in CNS PET/multimodal imaging’: After a short introduction of the basic concepts of AI, covering different methodologies such as Support Vector Machines and Deep Learning, we will focus on AI in CNS PET for classification and prediction tasks. We will discuss AI applications in neurodegenerative diseases such as Parkinson’s Disease and Amyotrophic Lateral Sclerosis.
 

JAVIER ARBIZU

May 21, 11.10 - 11.40am - "PET in Progressive Supranuclear-Palsy and Cortico-Basal Degeneration patients."
 
Progressive Supranuclear Palsy, and Corticobasal Degeneration are two neurodegenerative disorders characterized by Parkinsonism along with involvement of other brain cortical and subcortical regions. The ante mortem diagnosis of these disorders is extremely challenging with up to a quarter of these patients being misdiagnosed, particularly in the early stages of disease. While highly specific and sensitive imaging biomarkers of individual atypical parkinsonisms have not been identified yet, molecular PET imaging have improved our knowledge of the physiopathology and neuropathology of these disorders and are often used as supportive criteria for the differential diagnosis of these conditions. In this lecture, it will be provided a state-of-the-art overview of the use of PET in these conditions.

               Share Share

New comment:

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS